← Patent-cliff monitor Loss of exclusivity December 2040 latest FDA-listed patent expiry
Company BAUSCH HEALTH US LLC
Drug detail Brand name CABTREO Active ingredient ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE Strength 0.15%;3.1%;1.2% Dosage form GEL Route TOPICAL Modality Small molecule FDA approval October 2023 Marketing status RX
Listed patents Patent Expires Type 11389467 December 2040 product 12133859 July 2040 product 12128059 July 2040 product 12616710 July 2040 product 12138278 July 2040 product 8288434 August 2029 product 10624918 June 2029 use U-3713 10220049 June 2029 product 9561208 June 2029 product
Regulatory exclusivity Code Expires NP October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.